Natural Alternatives International (NAII) reported $130M in revenue for fiscal 2025, +14.1% year on year. That ranks #2839 by revenue among 2853 SEC filers and #319 in Healthcare. It posted a net loss of −$13.6M for the same year. Revenue has grown 0.8% a year on average since 2017 ($122M then). The fiscal 2025 balance sheet shows $153M in total assets, $3.8M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $130M | +14.1% | FY20252025-06-30 |
| Gross profitGrossProfit | $9.3M | +35.3% | FY20252025-06-30 |
| Operating incomeOperatingIncomeLoss | −$8.7M | −$126,000 | FY20252025-06-30 |
| Net incomeNetIncomeLoss | −$13.6M | −$6.4M | FY20252025-06-30 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $5.9M | +$7.4M | FY20252025-06-30 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.6M | +19.8% | FY20252025-06-30 |
| Total assetsAssets | $153M | −1.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $67.0M | −15.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $3.8M | −56.7% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $0 | $0 | FY20182018-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $35.5M | −$4.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Natural Alternatives International Inc
- Ticker
- NAII
- Exchange
- Nasdaq
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 06-30
- CIK
- 0000787253
Filings
- 10-QMay 19, 2026Open filing →
- 10-QFeb 13, 2026Open filing →
- 10-QNov 12, 2025Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| RxsightRXST | $134M | −$38.9M |
| Xtant MedicalXTNT | $134M | $4,973 |
| RidgetechRDGT | $132M | −$1.3M |
| Natural Alternatives InternationalNAII | $130M | −$13.6M |
| Niagen BioscienceNAGE | $129M | $17.4M |
| XencorXNCR | $126M | −$91.9M |
| Monte Rosa TherapeuticsGLUE | $124M | −$38.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Natural Alternatives International — Key figures |url=https://companiesranked.com/en/company/natural-alternatives-international |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Natural Alternatives International — Key figures. CompaniesRanked. https://companiesranked.com/en/company/natural-alternatives-internationalBibTeX
@misc{companiesranked-en-company-natural-alternatives-international-2026,
author = {{CompaniesRanked}},
title = {{Natural Alternatives International — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/natural-alternatives-international}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.